• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BLT
Click for more information
5.77% 5.5¢

BENITEC BIOPHARMA LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
BLTUS HEPATITIS C PRESENTATION05/08/13
BLTSHARE PURCHASE PLAN RAISES AUD2.8 MILLIONPRICE SENSITIVE31/07/13
BLTAppendix 4C - quarterlyPRICE SENSITIVE30/07/13
BLTTop 20 Security holders after consolidation26/07/13
BLTBecoming a substantial holder26/07/13
BLTBecoming a substantial holder26/07/13
BLTBecoming a substantial holder25/07/13
BLTChange of Director's Interest Notice25/07/13
BLTChange of Director's Interest Notice25/07/13
BLTChange of Director's Interest Notice25/07/13
BLTChange of Director's Interest Notice25/07/13
BLTs708 Cleansing Statement24/07/13
BLTAppendix 3B24/07/13
BLTAUD7.9 MILLION PLACEMENT COMPLETED23/07/13
BLTTIMETABLE FOR SPP AND SECURITIES CONSOLIDATION22/07/13
BLTCONSOLIDATED TRADING COMMENCES19/07/13
BLTConstitution17/07/13
BLTResults of Meeting17/07/13
BLTChairman's Address to Shareholders17/07/13
BLTLICENSEE CALIMMUNE STARTS CLINICAL TRIAL IN HIV AIDSPRICE SENSITIVE10/07/13
BLTPOSITIVE RAC AND FINAL PRE IND MEETINGPRICE SENSITIVE02/07/13
BLTSHARE PURCHASE PLAN24/06/13
BLTNotice of General Meeting/Proxy Form17/06/13
BLTs708 Cleansing Statement14/06/13
BLTAppendix 3B14/06/13
BLTUS COURT DECISION POSITIVE FOR BENITECPRICE SENSITIVE14/06/13
BLTR&D TAX CREDIT RECEIVEDPRICE SENSITIVE13/06/13
BLTFAVOURABLE RAC REVIEW12/06/13
BLTReinstatment to Official QuotationPRICE SENSITIVE06/06/13
BLTCAPITAL RAISING AUD7 MILLION PLACEMENTPRICE SENSITIVE06/06/13
BLTSuspension from official quotationPRICE SENSITIVE05/06/13
BLTTrading HaltPRICE SENSITIVE03/06/13
BLTLUNG CANCER PROGRAM INTO CLINICAL TRIAL IN EUROPEPRICE SENSITIVE03/06/13
BLTs708 Cleansing Statement29/05/13
BLTAppendix 3B28/05/13
BLTCORPORATE PRESENTATION MAY 201327/05/13
BLTPAIN PROGRAM PRESENTATION AT UK CONFERENCE22/05/13
BLTBLT - Response to ASX price queryPRICE SENSITIVE22/05/13
BLTUPDATE ON GENERAL MEETING TIMING10/05/13
BLTAppendix 4C - quarterlyPRICE SENSITIVE30/04/13
BLTHCV CLINICAL TRIAL APPLICATION SUBMITTED TO RACPRICE SENSITIVE17/04/13
BLTUCSD SELECTED AS SITE FOR HCV PHASE I II TRIALS16/04/13
BLTBENITEC LICENSEE SECURES ORHAN DRUG STATUSPRICE SENSITIVE15/04/13
BLTInitial Director's Interest Notice12/04/13
BLTKEVIN BUCHI APPOINTED TO BENITEC BOARD11/04/13
BLTPATENT ESTATE UPDATEPRICE SENSITIVE28/03/13
BLTs708 Cleansing Statement27/03/13
BLTAppendix 3B27/03/13
BLTFURTHER CAPITAL RAISING COMPLETEDPRICE SENSITIVE27/03/13
BLTDUKE SELESTED AS SITE FOR HEP C TRIALSPRICE SENSITIVE22/03/13
BLTBenitec China partner Biomics wins award20/03/13
BLTs708 Cleansing Statement18/03/13
BLTAppendix 3B12/03/13
BLTHEPATITIS C CLINICAL TRIAL PROGRESSPRICE SENSITIVE08/03/13
BLTReinstatment to Official QuotationPRICE SENSITIVE05/03/13
BLTCAPITAL RAISING COMPLETEDPRICE SENSITIVE05/03/13
BLTHalf Yearly Report and Accounts28/02/13
BLTAMENDMENT: CONTINUATION OF SUSPENSION28/02/13
BLTCONTINUATION OF SUSPENSION28/02/13
BLTSuspension from Official QuotationPRICE SENSITIVE27/02/13
BLTTrading HaltPRICE SENSITIVE25/02/13
BLTResponse to ASX queryPRICE SENSITIVE05/02/13
BLTAppendix 4C - quarterlyPRICE SENSITIVE31/01/13
BLTCORPORATE PRESENTATION AT CAPPELLO US INVESTOR CONFERENCE08/01/13
BLTPRESENTATION AT COWEN US INVESTOR SHOWCASE08/01/13
BLTBENITEC PRESENTS AT US-BASED INVESTOR CONFERENCES08/01/13
BLTAmended Change of Director's Interest Notice03/01/13
BLTAmended Change of Director's Interest Notice03/01/13
BLTAppendix 3B03/01/13
BLTChange of Director's Interest Notice03/01/13
BLTChange of Director's Interest Notice03/01/13
BLTCRO APPOINTED FOR HEPATITIS C TRIALPRICE SENSITIVE20/12/12
BLTChange of Director's Interest Notice10/12/12
BLTCross licenses with uniQure for Huntingtonss and Hep BPRICE SENSITIVE04/12/12
BLTOPMD PROGRAM DEMONSTRATES GENE SILENCINGPRICE SENSITIVE03/12/12
BLTAppendix 3B28/11/12
BLTInitiating Research Coverage20/11/12
BLTAGM VOTING RESULTS16/11/12
BLTAGM INVESTOR PRESENTATION16/11/12
BLTCHAIRMANS ADDRESS AGM 201216/11/12
BLTLung Cancer Program Gene SilencingPRICE SENSITIVE13/11/12
BLTAppendix 4C - quarterlyPRICE SENSITIVE31/10/12
BLTBENITEC AUSBIOTECH NOVEMBER 2012 PRESENTATION31/10/12
BLTTACERE ACQUISITION COMPLETED30/10/12
BLTS708 CLEANSING NOTICE30/10/12
BLTAppendix 3B30/10/12
BLTHepatitis C patent allowed in ChinaPRICE SENSITIVE22/10/12
BLT2012 Annual Report to shareholders17/10/12
BLTNotice of Annual General Meeting/Proxy Form17/10/12
BLTMICROCAP INVESTOR PRESENTATION17/10/12
BLTTACERE ACQUISITION IN PHASE I/II HEPATITIS C PROGRAMPRICE SENSITIVE11/10/12
BLTHEPATITIS C PATENT GRANTED IN CHINAPRICE SENSITIVE08/10/12
BLTPRESENTATION AT 6TH ANNUAL PAIN THERAPEUTICS SUMMIT03/10/12
BLTPAIN SUMMIT & INVESTOR CONFERENCE02/10/12
BLTPreliminary Final ReportPRICE SENSITIVE29/08/12
BLTSTANFORD UNIVERSITY RESEARCH AGREEMENTPRICE SENSITIVE13/08/12
BLTEFFICACY IN TRANSPLANT REJECTIONPRICE SENSITIVE30/07/12
BLTAppendix 4C - quarterlyPRICE SENSITIVE27/07/12
BLTPOSITIVE EUROPEAN REGULATOR DECISIONPRICE SENSITIVE23/07/12
BLTAppendix 3B20/07/12
BLTUS HEPATITIS C PRESENTATION
05/08/13
BLTSHARE PURCHASE PLAN RAISES AUD2.8 MILLION
31/07/13PRICE SENSITIVE
BLTAppendix 4C - quarterly
30/07/13PRICE SENSITIVE
BLTTop 20 Security holders after consolidation
26/07/13
BLTBecoming a substantial holder
26/07/13
BLTBecoming a substantial holder
26/07/13
BLTBecoming a substantial holder
25/07/13
BLTChange of Director's Interest Notice
25/07/13
BLTChange of Director's Interest Notice
25/07/13
BLTChange of Director's Interest Notice
25/07/13
BLTChange of Director's Interest Notice
25/07/13
BLTs708 Cleansing Statement
24/07/13
BLTAppendix 3B
24/07/13
BLTAUD7.9 MILLION PLACEMENT COMPLETED
23/07/13
BLTTIMETABLE FOR SPP AND SECURITIES CONSOLIDATION
22/07/13
BLTCONSOLIDATED TRADING COMMENCES
19/07/13
BLTConstitution
17/07/13
BLTResults of Meeting
17/07/13
BLTChairman's Address to Shareholders
17/07/13
BLTLICENSEE CALIMMUNE STARTS CLINICAL TRIAL IN HIV AIDS
10/07/13PRICE SENSITIVE
BLTPOSITIVE RAC AND FINAL PRE IND MEETING
02/07/13PRICE SENSITIVE
BLTSHARE PURCHASE PLAN
24/06/13
BLTNotice of General Meeting/Proxy Form
17/06/13
BLTs708 Cleansing Statement
14/06/13
BLTAppendix 3B
14/06/13
BLTUS COURT DECISION POSITIVE FOR BENITEC
14/06/13PRICE SENSITIVE
BLTR&D TAX CREDIT RECEIVED
13/06/13PRICE SENSITIVE
BLTFAVOURABLE RAC REVIEW
12/06/13
BLTReinstatment to Official Quotation
06/06/13PRICE SENSITIVE
BLTCAPITAL RAISING AUD7 MILLION PLACEMENT
06/06/13PRICE SENSITIVE
BLTSuspension from official quotation
05/06/13PRICE SENSITIVE
BLTTrading Halt
03/06/13PRICE SENSITIVE
BLTLUNG CANCER PROGRAM INTO CLINICAL TRIAL IN EUROPE
03/06/13PRICE SENSITIVE
BLTs708 Cleansing Statement
29/05/13
BLTAppendix 3B
28/05/13
BLTCORPORATE PRESENTATION MAY 2013
27/05/13
BLTPAIN PROGRAM PRESENTATION AT UK CONFERENCE
22/05/13
BLTBLT - Response to ASX price query
22/05/13PRICE SENSITIVE
BLTUPDATE ON GENERAL MEETING TIMING
10/05/13
BLTAppendix 4C - quarterly
30/04/13PRICE SENSITIVE
BLTHCV CLINICAL TRIAL APPLICATION SUBMITTED TO RAC
17/04/13PRICE SENSITIVE
BLTUCSD SELECTED AS SITE FOR HCV PHASE I II TRIALS
16/04/13
BLTBENITEC LICENSEE SECURES ORHAN DRUG STATUS
15/04/13PRICE SENSITIVE
BLTInitial Director's Interest Notice
12/04/13
BLTKEVIN BUCHI APPOINTED TO BENITEC BOARD
11/04/13
BLTPATENT ESTATE UPDATE
28/03/13PRICE SENSITIVE
BLTs708 Cleansing Statement
27/03/13
BLTAppendix 3B
27/03/13
BLTFURTHER CAPITAL RAISING COMPLETED
27/03/13PRICE SENSITIVE
BLTDUKE SELESTED AS SITE FOR HEP C TRIALS
22/03/13PRICE SENSITIVE
BLTBenitec China partner Biomics wins award
20/03/13
BLTs708 Cleansing Statement
18/03/13
BLTAppendix 3B
12/03/13
BLTHEPATITIS C CLINICAL TRIAL PROGRESS
08/03/13PRICE SENSITIVE
BLTReinstatment to Official Quotation
05/03/13PRICE SENSITIVE
BLTCAPITAL RAISING COMPLETED
05/03/13PRICE SENSITIVE
BLTHalf Yearly Report and Accounts
28/02/13
BLTAMENDMENT: CONTINUATION OF SUSPENSION
28/02/13
BLTCONTINUATION OF SUSPENSION
28/02/13
BLTSuspension from Official Quotation
27/02/13PRICE SENSITIVE
BLTTrading Halt
25/02/13PRICE SENSITIVE
BLTResponse to ASX query
05/02/13PRICE SENSITIVE
BLTAppendix 4C - quarterly
31/01/13PRICE SENSITIVE
BLTCORPORATE PRESENTATION AT CAPPELLO US INVESTOR CONFERENCE
08/01/13
BLTPRESENTATION AT COWEN US INVESTOR SHOWCASE
08/01/13
BLTBENITEC PRESENTS AT US-BASED INVESTOR CONFERENCES
08/01/13
BLTAmended Change of Director's Interest Notice
03/01/13
BLTAmended Change of Director's Interest Notice
03/01/13
BLTAppendix 3B
03/01/13
BLTChange of Director's Interest Notice
03/01/13
BLTChange of Director's Interest Notice
03/01/13
BLTCRO APPOINTED FOR HEPATITIS C TRIAL
20/12/12PRICE SENSITIVE
BLTChange of Director's Interest Notice
10/12/12
BLTCross licenses with uniQure for Huntingtonss and Hep B
04/12/12PRICE SENSITIVE
BLTOPMD PROGRAM DEMONSTRATES GENE SILENCING
03/12/12PRICE SENSITIVE
BLTAppendix 3B
28/11/12
BLTInitiating Research Coverage
20/11/12
BLTAGM VOTING RESULTS
16/11/12
BLTAGM INVESTOR PRESENTATION
16/11/12
BLTCHAIRMANS ADDRESS AGM 2012
16/11/12
BLTLung Cancer Program Gene Silencing
13/11/12PRICE SENSITIVE
BLTAppendix 4C - quarterly
31/10/12PRICE SENSITIVE
BLTBENITEC AUSBIOTECH NOVEMBER 2012 PRESENTATION
31/10/12
BLTTACERE ACQUISITION COMPLETED
30/10/12
BLTS708 CLEANSING NOTICE
30/10/12
BLTAppendix 3B
30/10/12
BLTHepatitis C patent allowed in China
22/10/12PRICE SENSITIVE
BLT2012 Annual Report to shareholders
17/10/12
BLTNotice of Annual General Meeting/Proxy Form
17/10/12
BLTMICROCAP INVESTOR PRESENTATION
17/10/12
BLTTACERE ACQUISITION IN PHASE I/II HEPATITIS C PROGRAM
11/10/12PRICE SENSITIVE
BLTHEPATITIS C PATENT GRANTED IN CHINA
08/10/12PRICE SENSITIVE
BLTPRESENTATION AT 6TH ANNUAL PAIN THERAPEUTICS SUMMIT
03/10/12
BLTPAIN SUMMIT & INVESTOR CONFERENCE
02/10/12
BLTPreliminary Final Report
29/08/12PRICE SENSITIVE
BLTSTANFORD UNIVERSITY RESEARCH AGREEMENT
13/08/12PRICE SENSITIVE
BLTEFFICACY IN TRANSPLANT REJECTION
30/07/12PRICE SENSITIVE
BLTAppendix 4C - quarterly
27/07/12PRICE SENSITIVE
BLTPOSITIVE EUROPEAN REGULATOR DECISION
23/07/12PRICE SENSITIVE
BLTAppendix 3B
20/07/12
refresh Created with Sketch. REFRESH
 

Top Stories

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Resolute Mining Ltd has told investors that a second payment has been made to the Mali government following the detention of three employees
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.